Question · Q2 2026
James (on behalf of Stephen Baxter) asked about Cardinal Health's modeling of GLP-1s, considering market changes like pricing, channel shifts, and the introduction of oral formulations. He inquired about any differences in revenue or earnings modeling for GLP-1s this year and the long-term outlook.
Answer
CEO Jason Hollar noted that oral GLP-1 contribution is currently slow but expected to grow, though not material for the current fiscal year. He suggested oral GLP-1s might have better cost-to-serve economics. He reiterated that GLP-1s are unlikely to be a significant driver for underlying profitability, despite being a substantial revenue contributor (6% of Q2 sales growth), and expects both injectables and orals to continue growing significantly in the near term.
Ask follow-up questions
Fintool can predict
CAH's earnings beat/miss a week before the call
